CN114057714B - 杂环基取代的氨基三唑的衍生物及其应用 - Google Patents
杂环基取代的氨基三唑的衍生物及其应用 Download PDFInfo
- Publication number
- CN114057714B CN114057714B CN202111385303.6A CN202111385303A CN114057714B CN 114057714 B CN114057714 B CN 114057714B CN 202111385303 A CN202111385303 A CN 202111385303A CN 114057714 B CN114057714 B CN 114057714B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 33
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 22
- 206010016654 Fibrosis Diseases 0.000 claims description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 230000004761 fibrosis Effects 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 5
- 229940126214 compound 3 Drugs 0.000 claims description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 206010014664 Endocardial fibrosis Diseases 0.000 claims description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 2
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000003334 potential effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 102100037328 Chitotriosidase-1 Human genes 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101000879661 Homo sapiens Chitotriosidase-1 Proteins 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- -1 3- (4-chlorobenzyl) -4-cyclohexylmorpholine Chemical compound 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical class NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 3
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000003547 hepatic macrophage Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 102000054350 human CHI3L1 Human genes 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RPHQMRWKOPBZQY-UHFFFAOYSA-N 2-amino-3-(4-chlorophenyl)propan-1-ol Chemical compound OCC(N)CC1=CC=C(Cl)C=C1 RPHQMRWKOPBZQY-UHFFFAOYSA-N 0.000 description 1
- NRCSJHVDTAAISV-UHFFFAOYSA-N 2-azaniumyl-3-(3,4-dichlorophenyl)propanoate Chemical group OC(=O)C(N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-UHFFFAOYSA-N 0.000 description 1
- OYBVODNMGYFPHN-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]morpholine Chemical compound C1=CC(Cl)=CC=C1CC1NCCOC1 OYBVODNMGYFPHN-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 description 1
- LXEJHPLLFBTVKJ-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]morpholin-3-one Chemical compound C1=CC(Cl)=CC=C1CC1NC(=O)COC1 LXEJHPLLFBTVKJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 101710151413 Chitinase 1 Proteins 0.000 description 1
- 101710203678 Chitinase-like protein Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 101710132290 Chitotriosidase-1 Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710107327 Endochitinase 1 Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000013227 macrophage apoptotic process Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医疗领域,具体涉及一种经杂环基取代的氨基三唑的衍生物及其应用,其具有如式A所示化合物的结构,该类化合物可用于制备治疗急性和慢性炎性疾病的药物,例如代谢性疾病或免疫性疾病,特别是纤维化疾病;体外研究结果显示,本发明提供的化合物与化合物DZ相比,对CHI3L1具有较强的抑制作用,远远强于化合物DZ,提示本发明的化合物具有更好的潜在的治疗肝纤维化的效果,可以预防肝硬化的发生,
Description
技术领域
本发明属于药物化学领域,具体涉及一种杂环基取代的氨基三唑的衍生物合成及其应用。更具体地,本发明涉及杂环基取代的氨基三唑的衍生物、包含该杂环基取代的氨基三唑的衍生物的药物组合物,以及该杂环基取代的氨基三唑的衍生物和其药物组合物在制备预防和/或治疗代谢性疾病或免疫学疾病的药物中的用途。
背景技术
纤维化(Fibrosis)是指正常器官或组织因受到超出自身修复能力的损伤后,受损处转化为由成纤维细胞与含有胶原蛋白、纤连蛋白的细胞外基质构成的纤维化组织的过程。在器官受到较轻微损伤时,组织中的成纤维细胞会参与修复过程,分泌细胞外基质并促进伤口收缩,之后受损部位很快会被再生的正常组织替代。但是,在器官或组织受到严重损伤之后,成纤维细胞会分泌过量的细胞外基质,加之机体自身的再生能力无法完全修复损伤,造成受损部位最终被纤维化组织替代、最终损害器官的形态与功能异常。纤维化是一种常见的疾病,全球范围内每4人中就有1人罹患纤维化。而在工业化国家中,45%的死亡都与纤维化造成的疾病有关。
纤维化是细胞外基质蛋白(包括胶原蛋白)的过度积累,发生在大多数类型的慢性肝病中。晚期肝纤维化会导致肝硬化、肝功能衰竭和门脉高压,通常需要肝移植。
几丁质酶3样1(Chitinase 3-like 1,CHI3L1,又称为YKL-40)是一种18-糖基水解酶相关分子,是酶失活的几丁质酶样蛋白家族的成员。在许多肝脏疾病期间,CHI3L1的血清水平与肝纤维化进展密切相关。有研究表明,CHI3L1是一种在衰老肝脏和肝硬化患者中过度表达的促纤维化因子,重组CHI3L1促进原代人肝星状细胞(HSC)的增殖和活化,这是肝纤维化的主要驱动因素([J].Proceedings of the National Academy of Sciences,2021,118(17).)。另外还有研究显示,在人和小鼠纤维化肝脏中,CHI3L1表达主要定位于肝巨噬细胞,与对照肝脏相比,纤维化肝脏中CHI3L1表达阳性的巨噬细胞的肝内积累显着增强。而敲除CHI3L1小鼠的肝纤维化显着改善,因为CHI3L1通过抑制Fas表达和以自分泌方式激Akt信号传导来抑制肝巨噬细胞凋亡,从而导致肝巨噬细胞积累和激活,加剧肝纤维化([J].Hepatology Research,2019,49(11):1316-1328)。诸多研究表明,CHI3L1通过促进肝血小板募集而导致对乙酰氨基酚引起的肝损伤([J].Elife,2021,10:e68571),且对伴有明显纤维化和肝硬化的慢性肝病患者具有良好的诊断价值([J]Chinese journal ofhepatology,2018,26(5):337-341)。
OATD 01(也称为GLPG 4716)是一种非甾体类抗炎小分子,由Onco ArendiTherapeutics开发,用于治疗哮喘、慢性阻塞性肺病(COPD)、间质性肺病和非酒精性脂肪性肝炎(NASH),为壳三糖苷酶-1(CHIT1)抑制剂,CHIT1活性在来自患有间质性肺病(如结节病和特发性肺纤维化(IPF))的患者的支气管肺泡灌洗(BALf)中显著升高,被认为是肺纤维化最佳生物标志物之一([J].European Respiratory Review,2020,29(156).)。PCT/IB2016/055269公开了一系列CHIT1抑制剂,其结构如下所示:
目前的CHIT1抑制剂还存在种类较少,抑制活性不够强等缺点,急需开发新型的CHIT1抑制剂。
发明内容
针对上述情况,本发明的目的在于提供一种具有药物活性的杂环基取代的氨基三唑的衍生物,其药物组合物及其在医疗领域的应用。
本发明提供如通式A所示的化合物或其可药用的盐,
其中,Y为-(CH2)b-,b选自1~4之间的任意一个整数;W为O或S中的任意一种;X为卤素;n选自0~2之间的任意一个整数。
本发明的一个具体实施例中,所述b选自1、2、3或4,优选为4。
本发明的一个具体实施例中,W为O。
本发明的一个具体实施例中,所述卤素为氟、氯、溴或碘。
本发明提供如通式B所示的化合物或其可药用的盐:
其中,Y为-(CH2)b-,b选自1~4之间的任意一个整数;W为O或S中的任意一种;X1为卤素。
本发明的一个具体实施例中,所述b选自1、2、3或4,优选为4。
本发明的一个具体实施例中,W为O。
本发明的一个具体实施例中,所述卤素为氟、氯、溴或碘。
本发明提供如通式C所示的化合物或其可药用的盐:
其中,Y为-(CH2)b-,b选自1~4之间的任意一个整数;W为O或S中的任意一种;X1或X2各自独立地为卤素。
本发明的一个具体实施例中,所述b选自1、2、3或4,优选为4。
本发明的一个具体实施例中,W为O。
本发明的一个具体实施例中,所述卤素为氟、氯、溴或碘。
本发明提供如通式D所示的化合物或其可药用的盐:
其中,所述X1选自氟、氯或溴中的任意一种,W为O。
本发明提供如通式E所示的化合物或其可药用的盐:
其中,所述X1或X2各自独立地选自氟、氯或溴中的任意一种,W为O。
本发明的一个具体实施例中,X1选自氟或氯,优选为氯;X2选自氟、氯或溴,优选为氯或溴。
本发明的一个具体实施例中,所述通式A所示的化合物或其可药用的盐选自如下所示任意一个化合物:
本发明的一个具体实施例中,所述通式A所示的化合物或其可药用的盐优选化合物3或其可药用的盐:
本发明的一个具体实施例中,所述可药用盐选自盐酸盐、氢溴酸盐、磷酸盐、硫酸盐、乙酸盐、草酸盐、马来酸盐、酒石酸盐、柠檬酸盐、琥珀酸盐、丙二酸盐、苯磺酸盐、苯甲酸盐、重硫酸盐,优选为盐酸盐。
本发明的一个实施例中,药物组合物可以利用一种或多种可药用的载体按照常规的方式加以配制。因此,本发明的活性化合物可以被配制成口服、口腔含化给药、鼻内、肠胃外(例如静脉内、肌内或皮下)或直肠给药的剂型,或者适用于通过吸入或吹入给药的剂型。本发明的化合物或其可药用的盐也可以被配制成持续释放的剂型。
本发明的一个实施例中,有效剂量的本发明的化合物或其可药用的盐可与如惰性稀释剂或某种载体一起口服。根据本发明的一些实施例,可将本发明的化合物包裹于明胶胶囊中或压制成片。为口服治疗的目的,本发明化合物可与赋形剂一起使用并以片剂、锭剂、胶囊、混悬剂、糖浆剂等形式使用。根据本发明的实施例,上述制剂应含有至少0.5%(w/w)的本发明的活性化合物,但可根据特定的剂型变化,其中占单位重量的4%至约70%是便利的。在这样的药物组合物中活性化合物的量应达到适当的剂量。
本发明的一个实施例中,关于口服给药,本发明的活性化合物例如可通过常规手段与可药用的赋形剂加以配制成片剂或胶囊,赋形剂例如粘合剂,填充剂,润滑剂,崩解剂或润湿剂。片剂可以通过本领域熟知的方法加以包衣。用于口服给药的液体制剂,如可以采用溶液、糖浆或悬液,或挥发为干燥产物,使用前用水或其他合适的载体再生。这类液体制剂可利用药用的添加剂通过常规手段加以制备,添加剂例如悬浮剂,乳化剂,非水性载体和防腐剂。
本发明的一个实施例中,当本发明的活性化合物用于胃肠外施用时,可将本发明提供的化合物与无菌水或有机介质组合形成可注射的溶液或悬液。
本发明的一个实施例中,本发明的活性化合物可以被配制成直肠组合物,例如栓剂或保留灌肠剂,例如含有常规的栓剂基质,例如可可脂或其他甘油酯。
本发明还提供一种通式A所示的化合物或其可药用的盐或其药物组合物在制备调控几丁质酶3样1(Chitinase 3-like 1,CHI3L1)的药物中的用途,其中所述药物任选包含另外一种或多种调节哺乳动物纤维化疾病的活性剂。
本发明的一个实施例中,所述调控包括但不限于对CHI3L1的抑制活性或拮抗活性。
本发明的一个实施例中,本发明还提供一种通式A所示的化合物或其可药用的盐或其药物组合物在制备治疗纤维化性疾病的药物中的用途。
本发明的一个具体实施例中,所述纤维化性疾病选自心内膜纤维化,肝纤维化,特发性肺纤维化,间质性肺病,纵隔纤维化,腹膜纤维化,脾脏纤维化或肾纤维化中的任意一种,优选为肝纤维化或特发性肺纤维化中的任意一种。
本发明的一个具体实施例中,所述肝纤维化选自轻度肝硬化,中度肝硬化或重度肝硬化中的任意一种。
本发明的一个具体实施例中,所述肝纤维化优选为轻度肝硬化或中度肝硬化中的任意一种。
本发明具有如下有益效果:本发明提供的化合物为一种CHI3L1抑制剂,因CHI3L1的血清水平与肝纤维化进展密切相关,因此具有潜在的治疗肝纤维化的医药价值。
体外研究结果显示,本发明提供的化合物与化合物DZ相比,对CHI3L1具有较强的抑制作用,远远强于化合物DZ,提示本发明的化合物具有更好的潜在的治疗肝纤维化的效果,可以预防肝硬化的发生。
具体实施方式
术语“包含”为开放式表达,即包括本发明所指明的内容,但并不排除其他方面的内容。应当理解,术语“包含”可以涵盖封闭式的含义,即“由…组成”。
像本发明所描述的,本发明的化合物可以任选地被一个或多个取代基所取代,如上面的通式化合物或者像实施例中特定的实例、子类。应了解术语“任选取代的”与术语“取代或未取代的”可以交换使用。一般而言,术语“取代的”表示所给结构中的一个或多个氢原子被特定取代基所取代。除非其他方面表明,任选取代的基团可以在该基团各个可取代的位置进行取代。当所给出的结构式中不只一个位置能被选自特定基团的一个或多个取代基所取代时,那么取代基可以相同或不同地在各个位置取代。
另外,需要说明的是,除非以其他方式明确指出,在本发明中所采用的描述方式“分别独立地为”应做广义理解,其既可以是指在不同基团中,相同符号之间所表达的具体选项之间互相不影响,也可以表示在相同的基团中,相同符号之间所表达的具体选项之间互相不影响。
实施例
下面详细描述本发明的实施例。下面描述的实施例是示例性的,仅用于解释本发明,而不能理解为对本发明的限制。除非另外指明,本文所指的比例、百分比等均以重量计。
合成实施例
实施例1
N5-(4-(3-(4-氯苄基)吗啉代)环己基)-1H-1,2,4-三唑-3,5-二胺(化合物1)的合成,合成路线见下式:
步骤1:2-氨基-3-(4-氯苯基)丙-1-醇(化合物1-2)的合成
在0℃下,向化合物1-1的无水THF(3mL/mmol)的混悬液中逐滴加入硼烷-二甲基硫醚复合物(相当于化合物1-1的3N),移除冷却浴并将反应混合物回流过夜,薄层色谱显示反应完全。将混合物冷却至室温,缓慢加入6M HCl(相当于化合物1-1的8N)。将混合物回流1.5-2h,并冷却至室温,用4M NaOH将pH调至10。产物用乙酸乙酯萃取3次,合并萃取液、经硫酸镁干燥、过滤并真空浓缩。用乙醚打浆后滤出得到淡黄色固体。
MS(ESI)m/z185.7/187.7(M+1)+
步骤2:2-氯-N-(1-(4-氯苯基)-3-羟基丙-2-基)乙酰胺(化合物1-3)的合成
0-5℃下,向化合物1-2的THF(6mL/mmol)溶液中加入三乙胺(相当于化合物1-2的1.2N),在0-5℃下缓慢加入化合物a(相当于化合物1-2的1N),然后将化合物搅拌20-40min,薄层色谱显示反应完全。然后向混合物中加入二乙醚,并将所得混合物依次用1M HCl、1MNaOH、盐水洗涤,经硫酸镁干燥,过滤并旋干得到白色至淡黄色粗产物。
MS(ESI)m/z262.2/264.2(M+1)+
步骤3:5-(4-氯苄基)吗啉-3-酮(化合物1-4)的合成
向化合物1-3的THF的溶液(10mL/mmol)中加入NaH(相当于化合物1-3的3N)使反应混合物在室温下搅拌2-3h。逐滴加入盐水小心猝灭过量NaH,再加入等于THF的初始体积的盐水,分离有机相,且用二乙醚萃取水相,合并有机萃取相,经硫酸镁干燥,过滤并旋干溶剂。粗产物直接投入下一步反应中。
MS(ESI)m/z226.2/228.2(M+1)+
步骤4:3-(4-氯苄基)吗啉(化合物1-5)的合成
向化合物1-4的THF的溶液中(3mL/mmol)中加入BH3 DMS复合物(相当于化合物1-4的3N),反应混合物回流3h,薄层色谱显示反应完全。将反应物冷却至室温,小心加入2MHCl(相当于化合物1-4的6N)。将所得反应混合物回流2h,冷却回至室温。然后通过逐滴添加6MNaOH将溶液的pH调节至强碱性(约10)。分离有机相,并用二乙醚萃取水相。然后合并的有机萃取相,经硫酸镁干燥,过滤并旋干溶剂。在大多数情况下,粗产物直接投入下一步反应中。
MS(ESI)m/z212.2/214.2(M+1)+
步骤5:3-(4-氯苄基)-4-环己基吗啉(化合物1-6)的合成
将步骤5的产物溶于无水MeOH(6mL/mmol)中,加入环己酮(3mL/mmol),冰醋酸(10mL/mmol)和三乙酰氧基硼氢化钠(4mL/mmol),将混合物在50-55℃下反应16h。将反应混合物浓缩后,再溶解在乙酸乙酯中,用饱和氯化钠水溶液洗涤,用无水硫酸钠干燥,过滤,减压蒸发滤液以除去溶剂以产生标题化合物,产物不经纯化直接用于下一步。
MS(ESI)m/z279.14/279.80(M+1)+
步骤6:4-(3-(4-氯苄基)吗啉代)环己-1-胺(化合物1-7)的合成
将化合物1-6溶于干燥THF(8mL/mmol)中,氩气气氛下冷却至0℃,然后向化合物1-6的THF溶液中快速加入3M硼烷,将该溶液在0℃下搅拌10min,然后在室温下搅拌90min。将反应混合物再次冷却至0℃并以加入羟胺-O-磺酸(相当于化合物1-6的3N)。移除冰浴并将反应混合物在室温下搅拌2h。加入1N HCl(25mL)和乙醚(20mL)并继续搅拌10min。分离各相并弃去有机相。通过小心加入50%NaOH溶液使水相呈碱性,然后用乙醚(3×30mL)萃取。用硫酸镁干燥有机相并蒸发溶剂,得到粗产品直接投入下一步反应中。
MS(ESI)m/z308.17/308.85(M+1)+
步骤7:N5-(4-(3-(4-氯苄基)吗啉代)环己基)-1H-1,2,4-三唑-3,5-二胺(化合物1)的合成
将化合物1-7、无水K2CO3(相当于化合物1-7的2N)和S,S'-二甲基-N-氰基-二硫代亚氨基碳酸酯(相当于化合物1-7的1.2N)溶解于ACN中,并将混合物回流12h,薄层色谱检测反应完全后,然后添加一水合肼(相当于化合物1-7的3-5N)并将反应物再进一步回流6h,此后将其冷却至室温并滤出固体,将滤液真空浓缩,并通过从乙醚/乙酸乙酯混合溶剂中(体积比3:1)中结晶或通过反相C-18硅胶色谱纯化得到淡黄色粗产物。
产物核磁信息如下:
1H NMR(400MHz,CDCl3):δ1.53-1.89(6H,1.61(ddt,J=12.8,10.3,2.8Hz),1.75(dq,J=12.9,2.8Hz),1.82(dq,J=12.8,2.8Hz)),1.93-2.09(2H,2.01(dtd,J=12.9,10.3,2.8Hz),2.42-2.59(2H,2.50(ddd,J=14.0,10.2,2.5Hz),2.51(ddd,J=14.0,3.1,2.5Hz),2.60-2.76(3H,2.66(tt,J=10.3,2.8Hz),2.71(d,J=5.2Hz),2.93(1H,dtd,J=10.2,5.2,2.5Hz),3.50-3.81(5H,3.57(ddd,J=14.2,3.1,2.5Hz),3.61(ddd,J=14.2,10.2,2.5Hz),3.66(dd,J=15.4,2.5Hz),3.73(dd,J=15.4,10.2Hz),3.74(quint,J=2.8Hz)),7.23-7.47(4H,7.29(ddd,J=8.3,1.3,0.5Hz),7.41(ddd,J=8.3,1.3,0.5Hz)).
MS(ESI)m/z390.19/390.91(M+1)+
实施例2
N5-(4-(3-(4-氟苄基)吗啉代)环己基)-1H-1,2,4-三唑-3,5-二胺(化合物2)的合成
按实施例1方法制备化合物,但用2-氨基-3-(4-氟苯基)丙酸(市售)替代2-氨基-3-(4-氯苯基)丙酸。
产物核磁信息如下:
1H NMR(400MHz,CDCl3):δ1.53-1.89(6H,1.61(ddt,J=12.8,10.3,2.8Hz),1.75(dq,J=12.9,2.8Hz),1.82(dq,J=12.8,2.8Hz),1.93-2.09(2H,2.01(dtd,J=12.9,10.3,2.8Hz),2.42-2.75(5H,2.50(ddd,J=14.0,10.2,2.5Hz),2.51(ddd,J=14.0,3.1,2.5Hz),2.65(tt,J=10.3,2.8Hz),2.69(d,J=5.1Hz),2.69(d,J=5.1Hz)),2.94(1H,dtd,J=10.2,5.1,2.5Hz),3.50-3.83(5H,3.57(ddd,J=14.2,3.1,2.5Hz),3.61(ddd,J=14.2,10.2,2.5Hz),3.66(dd,J=15.4,2.5Hz),3.75(dd,J=15.4,10.2Hz),3.74(quint,J=2.8Hz)),6.97-7.19(4H,7.03(ddd,J=8.4,1.3,0.5Hz),7.13(ddd,J=8.4,1.2,0.5Hz)).
MS(ESI)m/z374.22/374.46(M+1)+
实施例3
N5-(4-(3-(3,4-二氯苄基)吗啉代)环己基)-1H-1,2,4-三唑-3,5-二胺(化合物3)的合成
按实施例1方法制备化合物,但用2-氨基-3-(3,4-二氯苯基)丙酸(市售)替代2-氨基-3-(4-氯苯基)丙酸。
产物核磁信息如下:
1H NMR(400MHz,CDCl3):δ1.53-1.89(6H,1.61(ddt,J=12.8,10.3,2.8Hz),1.75(dq,J=12.9,2.8Hz),1.82(dq,J=12.8,2.8Hz),1.92-2.09(2H,2.01(dtd,J=12.9,10.3,2.8Hz),2.42-2.59(2H,2.50(ddd,J=14.0,10.2,2.5Hz),2.51(ddd,J=14.0,3.1,2.5Hz)),2.60-2.78(3H,2.67(tt,J=10.3,2.8Hz),2.73(d,J=5.1Hz),2.94(1H,dtd,J=10.2,5.1,2.5Hz),3.50-3.84(5H,3.57(ddd,J=14.2,3.1,2.5Hz),3.61(ddd,J=14.2,10.2,2.5Hz),3.67(dd,J=15.5,2.5Hz),3.75(dd,J=15.5,10.2Hz),3.74(quint,J=2.8Hz)),7.26-7.51(3H,7.32(dd,J=8.0,1.2Hz),7.41(dd,J=8.0,0.6Hz),7.46(dd,J=1.2,0.6Hz)).
MS(ESI)m/z424.15/425.36(M+1)+
实施例4
N5-(4-(3-(3-溴-4-氯苄基)吗啉代)环己基)-1H-1,2,4-三唑-3,5-二胺(化合物4)的合成
按实施例1方法制备化合物,但用2-氨基-3-(3-溴-4-氯苯基)丙酸(市售)替代2-氨基-3-(4-氯苯基)丙酸。
产物核磁信息如下:
1H NMR(400MHz,CDCl3):δ1.53-1.89(6H,1.61(ddt,J=12.8,10.3,2.8Hz),1.75(dq,J=12.9,2.8Hz),1.82(dq,J=12.8,2.8Hz),1.92-2.09(2H,2.01(dtd,J=12.9,10.3,2.8Hz),2.42-2.59(2H,2.50(ddd,J=14.0,10.2,2.5Hz),2.51(ddd,J=14.0,3.1,2.5Hz)),2.65-2.78(3H,2.71(tt,J=10.3,2.8Hz),2.73(d,J=5.2Hz),2.93(1H,dtd,J=10.2,5.2,2.5Hz),3.50-3.84(5H,3.57(ddd,J=14.2,3.1,2.5Hz),3.61(ddd,J=14.2,10.2,2.5Hz),3.67(dd,J=15.5,2.5Hz),3.75(dd,J=15.5,10.2Hz),3.74(quint,J=2.8Hz)),7.24(1H,dd,J=8.2,1.2Hz),7.32-7.45(2H,7.38(dd,J=8.2,0.6Hz),7.38(dd,J=1.2,0.6Hz)).
MS(ESI)m/z468.10/469.81(M+1)+
对比测试例
本发明下述的作为对比例的化合物DZ如下式所示,参照专利CN108290863B所述实施例1所述方法进行制备,
测试例1
人CHI3L1活性测定
参照试剂盒人几丁质酶3样1Quantikine ELISA试剂盒所述方法测定(CatalogNo.:MBS765293)化合物1-4以及DZ的活性,方法参考Rehli M等人公开的测试方法([J].Journal of Biological Chemistry,2003,278(45):44058-44067.)
测试原理:
该试剂盒基于夹心酶联免疫吸附测定技术。捕获抗体预包被到96孔板上。并以生物素偶联抗体作为检测抗体。随后将标准品、测试样品(化合物1-4,DZ)和生物素偶联的检测抗体加入孔中,并用洗涤缓冲液洗涤。加入HRP-链霉亲和素,用洗涤缓冲液洗去未结合的偶联物。TMB底物用于观察HRP酶促反应。TMB经HRP催化生成蓝色产物,加入酸性终止液后变为黄色。黄色的密度与板中捕获的目标样品量成正比。阅读O.D.在酶标仪上450nm处的吸光度,然后可以计算目标的浓度。
测试步骤:
1.在预涂板上分别设置标准、测试样品(用样品稀释缓冲液至少稀释1/2)、对照(空白)孔,然后记录它们的位置。建议重复测量每个标准和样品。在添加标准、样品和对照(空白)孔之前洗板2次。
2.准备标准品:将100μL的零管、1st tube、2nd tube、3rd tube、4th tube、5th tube、6th tube和样品稀释缓冲液(空白)分装到标准孔中。
3.加样:将100μL适当稀释的样品加入待测样品孔中。
4.孵育:盖上盖子,37℃孵育90分钟。
5.洗涤:取下盖子并丢弃板内容物,用洗涤缓冲液洗涤板2次。任何情况下都不要让孔完全干燥。
6.生物素标记抗体:将100μL生物素标记抗体工作液加入上述孔中(标准孔、待测孔和空白孔)。在每孔底部加入溶液,不要接触侧壁,盖上板并在37℃下孵育60分钟。
7.清洗:取下盖子,用Wash Buffer清洗板3次,每次让Wash Buffer在孔中停留1-2分钟。
8.HRP-Streptavidin Conjugate(SABC):每孔加入100μL SABC WorkingSolution,盖上平板,37℃孵育30分钟。
9.清洗:取下盖子,用Wash Buffer洗板5次,每次让Wash Buffer在孔中停留1-2分钟。
10.TMB Substrate:每孔加入90μLTMB Substrate,盖上平板,37℃避光孵育10-20分钟。(注:反应时间可根据实际颜色变化缩短或延长,但不得超过30分钟。当标准孔出现明显梯度时可终止反应。)
11.停止:每孔加入50μL停止液。颜色会立即变黄。Stop Solution的添加顺序应与TMB Substrate Solution相同。
12.OD测量:读取O.D.加入终止液后立即在酶标仪中测定450nm处的吸光度。
表1中公开的化合物具有通常在约0.01μM至约100μM范围内的IC50值。相关值范围如下所示:
#表示<0.1μM;##表示<0.1-1μM;###表示<1-10μM;####表示>100μM;
表1各化合物体外酶抑制活性测试结果
化合物 | 对人CHI3L1的活性级别IC50 |
化合物1 | ## |
化合物2 | ## |
化合物3 | # |
化合物4 | ## |
化合物DZ | #### |
结果
目前的体内和体外结果提供证据表明CHI3L1在肝纤维化中起核心作用,并支CHI3L1在增加衰老肝脏对纤维化进展的易感性中的作用,CHI3L1可能为特定的抗纤维化治疗开辟新的治疗思路,以减少或预防肝纤维化的并发症(Nishimura N,De Battista D,McGivern D R,et al.Chitinase 3-like 1is a profibrogenic factor overexpressedin the aging liver and in patients with liver cirrhosis[J].Proceedings of theNational Academy of Sciences,2021,118(17).)。
根据上述表1结果可知,体外实验结果表明本发明的化合物(特别是化合物3对CHI3L1具有较强的抑制作用,远远强于化合物DZ,提示本发明的化合物具有更好的潜在的治疗肝纤维化的效果,预防肝硬化的发生,能够具有缓解重度肝病进程的作用的潜在医药应用价值。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (10)
4.如权利要求3所述的如通式A所示的化合物或其可药用的盐,其特征在于,所述X1选自氟或氯;X2选自氟、氯或溴。
7.一种药物组合物,其特征在于,包含治疗有效量的,如权利要求1-6中任一项所述的如通式A所示的化合物或其可药用的盐和药学上可接受的载体。
8.如权利要求1-6中任一项所述的如通式A所示的化合物或其可药用的盐或如权利要求7所述的药物组合物在制备治疗纤维化性疾病的药物中的用途。
9.如权利要求8所述的用途,其特征在于,所述纤维化性疾病选自心内膜纤维化,肝纤维化,特发性肺纤维化,间质性肺病,纵隔纤维化,腹膜纤维化,脾脏纤维化或肾纤维化中的任意一种。
10.如权利要求9所述的用途,其特征在于,所述肝纤维化选自轻度肝硬化,中度肝硬化或重度肝硬化中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111385303.6A CN114057714B (zh) | 2021-11-22 | 2021-11-22 | 杂环基取代的氨基三唑的衍生物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111385303.6A CN114057714B (zh) | 2021-11-22 | 2021-11-22 | 杂环基取代的氨基三唑的衍生物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114057714A CN114057714A (zh) | 2022-02-18 |
CN114057714B true CN114057714B (zh) | 2023-07-14 |
Family
ID=80278682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111385303.6A Active CN114057714B (zh) | 2021-11-22 | 2021-11-22 | 杂环基取代的氨基三唑的衍生物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114057714B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL415078A1 (pl) * | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
-
2021
- 2021-11-22 CN CN202111385303.6A patent/CN114057714B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114057714A (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2271341B1 (en) | Specific inhibitors for vascular endothelial growth factor receptors | |
RU2235725C2 (ru) | Производные имидазопиридина, способ их получения и промежуточные соединения, фармацевтический препарат на их основе (варианты), способ ингибирования секреции желудочной кислоты и способ лечения состояний, в которые вовлечено инфицирование h.pylori | |
KR101723707B1 (ko) | Pgds 저해 작용을 갖는 피페라진 화합물 | |
US20010051642A1 (en) | Method for treating Alzheimer's disease | |
KR101421785B1 (ko) | 프로스타글란딘 d 합성 효소를 저해하는 피페라진 화합물 | |
WO2005087729A1 (fr) | Derives de 5-hydroxyindol-3-carboxylate et leur utilisation | |
WO2000034255A1 (en) | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin | |
US20110105567A1 (en) | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | |
WO2014138368A1 (en) | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | |
CN114375193B (zh) | 甲状腺激素受体β激动剂化合物 | |
JP2019512459A (ja) | 7員環化合物、その調製方法、その医薬組成物、およびその使用 | |
US4868193A (en) | Styryl tetrazoles and anti-allergic use thereof | |
JP2002540198A (ja) | 喘息、アレルギー、および炎症性疾患の治療のための化合物および方法 | |
EP2188277B1 (en) | Quinazolinedione chymase inhibitors | |
US4801598A (en) | Dihydropyridine anti-allergic and anti-inflammatory agents | |
CN114057714B (zh) | 杂环基取代的氨基三唑的衍生物及其应用 | |
JP4039588B2 (ja) | 置換された2−ナフトイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬 | |
MX2014011648A (es) | Derivado de acido nipecotico y el uso del mismo para propositos medicos. | |
CN109836423B (zh) | 一类预防或治疗肺纤维化疾病的新化合物、制备方法及其用途 | |
US4859686A (en) | Dihydropyridine anti-allergic and anti-inflammatory agents | |
JPH02229168A (ja) | ピラゾロン誘導体 | |
WO2003082263A1 (en) | Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases | |
WO2013161980A1 (ja) | シクロヘキサンジアミド誘導体及びその医薬用途 | |
US5753667A (en) | 1-oxo-2- (phenylsulphonylamino) pentylpiperidine derivatives, their preparation and their therapeutic application | |
OA12256A (en) | Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |